THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) participated in the International Society of Gynecological Endocrinology (ISGI) Congress in Florence, Italy. At the symposium on “The Effects of Progesterone Receptor Modulators in Female Reproductive Health with Emphasis on the Endometrium”, chaired by Professor Irving Spitz and Dr. Regine Sitruk Ware, the clinical efficacy and integrated safety data as well as important new histology information derived from endometrial biopsies from the recently completed endometriosis and uterine fibroid studies were presented. Dr. Andre van As, Repros’ Chief Medical Officer, presented the clinical data and Dr. George Mutter (Associate Professor of Pathology, Harvard Medical School, Department of Pathology Brigham and Women’s Hospital) presented the histological findings from the endometrial biopsies in detail. The data presented at the Congress came from the clinical studies reported preliminarily in April and June 2007. The preliminary histology results were reported on July 25, 2007. The relevance of the findings presented at the Florence meeting and their impact on the future clinical development of Proellex® is summarized below.
